Infectious disease therapeutics market is driven by the growing prevalence rates of infectious diseases, increased healthcare expenditure and increased funding of governments on prevention and management of infectious diseases. In addition, increased geriatric population and use of direct acting antiviral drugs are fuelling the growth of infectious diseases therapeutics market. However, patent expiry of many infectious disease drugs and increase number of generic alternatives hindering the market revenue of infectious disease therapeutics market.

A sample of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-infectious-disease-therapeutics-market/#ulp-4H8Z4LpNMLEuOnnx

Infectious disease therapeutics market segmented based on drug class, disease indication, and distribution channel

Based on drug class, infectious disease therapeutics market is segmented into
Anti-Bacterial
Anti-Viral
Anti-Parasite
Anti-Fungal
Others

Based on disease indication, infectious disease therapeutics market is segmented into
HIV/AIDS
Influenza
Hepatitis
Malaria
TB
Others

Based on distribution channel, infectious disease therapeutics market is segmented into
Hospital Pharmacy
Retail Pharmacy
Others

To view TOC of this report is available upon request @
https://www.precisionbusinessinsights.com/market-reports/global-infectious-disease-therapeutics-market/#ulp-c654SbFYO64MsOhu

Market players focusing on mergers, acquisitions and collaborations to increase revenue share in the market. For instance, in August 2016, Pfizer acquired AstraZeneca’s late-stage small molecule anti-infectives business for development and commercialization outside the U.S. In addition, market players investing on research and development to introduce new drugs and to strengthen their position in infectious disease therapeutics market. Some of the pipeline anti infectives include avycaz (ceftazidime and avibactam), bictegravir (Anti HIV), cabotegravir (Anti HIV). Patent expiry of blockbuster anti-infectives such as Tamiflu, cubicin and ambisome are expected to negatively effect the infectious disease therapeutics market.

Need more information about this report @
https://www.precisionbusinessinsights.com/market-reports/global-infectious-disease-therapeutics-market/#ulp-14mlyhjMGhVjZqa3

Geographically infectious disease therapeutics market has been segmented into following regions viz. North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. North America dominates the infectious disease therapeutics market owing to high prevalence rates of infectious diseases and rise in ageing population. According to scientific data from Princeton University 2015, rising trend in consumption of anti-infectives has increased in BRICS nation. In the last few years, there was an increase in use of antibiotics in Asian countries like India and China and some parts of Africa. Factors such as rapidly developing healthcare infrastructure on the grounds of emerging medical tourism industry along with government initiative to boost biotechnology sector of the respective country are fuelling the growth of the infectious disease therapeutics market in Asia Pacific region.

Get access to full summary @
https://www.precisionbusinessinsights.com/market-reports/global-infectious-disease-therapeutics-market/

Some of the players in infectious disease therapeutics market are GlaxoSmithKline Plc (U.K.), Johnson & Johnson Services, Inc. (U.S.), Merck & Co, Inc. (U.S.), Pfizer Inc. (U.S.), Novartis AG. (Switzerland), AbbVie Inc. (U.S.), Astellas Pharma Inc. (Japan), AstraZeneca (U.K.), Auritec Pharmaceuticals Inc. (U.S.), Bayer AG (Germany), Modified Polymer Components, Inc. (Bristol-Myers Squibb) (U.S.), Chimerix Inc. (U.S.), Eli Lilly and Company (U.S.), Isis Pharmaceuticals (U.S.), Mitsubishi Chemical Holdings Corporation (Mitsubishi Tanabe Pharma) (Japan), Sanofi S.A. (France) and Gilead Sciences (U.S.) to name a few.